Title |
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update
|
---|---|
Published in |
Clinical Pharmacology & Therapeutics, April 2017
|
DOI | 10.1002/cpt.668 |
Pubmed ID | |
Authors |
JA Johnson, KE Caudle, L Gong, M Whirl‐Carrillo, CM Stein, Scott, MT Lee, BF Gage, Kimmel, MA Perera, JL Anderson, M Pirmohamed, TE Klein, NA Limdi, LH Cavallari, M Wadelius |
Abstract |
This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2-3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry. This article is protected by copyright. All rights reserved. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | <1% |
Unknown | 451 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 65 | 14% |
Student > Master | 59 | 13% |
Researcher | 49 | 11% |
Student > Ph. D. Student | 41 | 9% |
Student > Doctoral Student | 23 | 5% |
Other | 80 | 18% |
Unknown | 135 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 80 | 18% |
Pharmacology, Toxicology and Pharmaceutical Science | 77 | 17% |
Medicine and Dentistry | 66 | 15% |
Agricultural and Biological Sciences | 23 | 5% |
Unspecified | 8 | 2% |
Other | 47 | 10% |
Unknown | 151 | 33% |